J Clin Oncol 29: 2011 (suppl)
Author(s):
J. Pan

Abstract:

Background: The study objective was to evaluate the efficacy and safety of recombinant adeno-viral human p53 gene (rAd-p53) combined with radiotherapy (RT) in treatment of advanced cervical carcinoma. Methods: Patients aged ≥18 years, with stage IIB–IVA cervical carcinoma, expecting to live more than 3 months, without any anti-tumor treatment in 2 weeks, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2 were randomly assigned in two groups: experimental group (EG) receiving weekly intratumoral injection of 1–4×10^{12} rAd-p53 viral particles (VP) for 6 weeks combined with 1.8–2Gy/f of external beam therapy in Point B (total dose of 45–50Gy) and 7Gy/f of high dose rate (HDR) brachytherapy in Point A (total dose of 70 Gy) in 6 week; control group (CG) receiving the same dose of RT. The response rate, long-term efficacy and adverse effects were evaluated. Results: Thirty-nine eligible patients, 21 in EG and 18 in CG, were enrolled between 2008 and 2009. In EG, 11 patients (52.4%) achieved a complete response (CR), 10 (47.6%) had a partial response (PR), and the overall response rate (RR) was 100%. In CG, there was 8 (44.4%) CR, 5 (27.8%) PR, 3 (16.7%) stable diseases (SD) and 2 (11.1%) progressive diseases (PD), and the RR was 72.2%. The RR difference is statistically significant (Fisher's Exact Test: p=0.0149). In EG, 15 (71.4%) patients has self-limited fever and 8 (38.1%) had a grade 1 or 2 myelosuppression. In CG, 9 patients (50%) had a grade 1 or 2 myelosuppression. The result of long-term efficacy is not available at this time. Conclusions: Intratumoral rAd-p53 injection combined with radiotherapy significantly increases overall response rate. The main adverse effect of rAd-p53 is fever.